PI3K/AKT/mTOR通路抑制剂单药治疗卵巢癌疗效的Meta分析
该系统评价纳入19项研究共233例晚期或复发卵巢癌患者,评估PI3K/AKT/mTOR抑制剂单药治疗的临床获益率(CBR)和客观缓解率(ORR)。汇总CBR为32%(95%CI 20-44%),ORR为3%(95%CI 0-6%);排除稳定疾病不足6个月后CBR降至7%(95%CI 2-13%)。药物相关3-4级不良事件总体比例为36%。结论认为单药疗效有限,现有生物标志物选择未能显著改善CBR,不建议在临床试验外启动此类治疗。
要点
- PI3K/AKT/mTOR抑制剂单药在晚期或复发卵巢癌中汇总CBR为32%,ORR仅3%。
- 排除SD<6个月后CBR降至7%,提示真实获益有限。
- 药物相关3-4级不良事件总体比例为36%,毒性负担明显。
核心结论
- PI3K/AKT/mTOR抑制剂单药在晚期复发卵巢癌中疗效仅限于小部分亚组,现有生物标志物选择未显著改善CBR。
- 鉴于毒性特征,不建议在临床试验外启动此类治疗。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane Library,纳入19项研究报告PI3K/AKT/mTOR抑制剂治疗卵巢癌的研究,共233例患者。
- 主要终点为临床获益率(CBR,含完全缓解、部分缓解和稳定疾病),次要终点为客观缓解率(ORR)和药物相关3-4级不良事件。
主要发现
- 晚期或复发卵巢癌患者接受PI3K/AKT/mTOR抑制剂治疗的汇总CBR为32%(95%CI 20-44%),ORR为3%(95%CI 0-6%)。
- 基于现有PI3K/AKT/mTOR生物标志物(如基因组改变或PTEN蛋白表达缺失)选择患者的研究CBR为42%(95%CI 23-62%),未选择人群为27%(95%CI 14-42%),差异无统计学意义(P=0.217)。
- 排除稳定疾病不足6个月作为获益后,汇总CBR为7%(95%CI 2-13%)。
- 药物相关3-4级不良事件总体比例为36%。
关键数值与推荐
- 主要终点CBR定义为完全缓解、部分缓解和稳定疾病患者的比例。
- 次要终点ORR定义为完全缓解和部分缓解的比例。
临床怎么用
- 现有证据不支持在临床试验外对晚期或复发卵巢癌患者启动PI3K/AKT/mTOR抑制剂单药治疗。
- 患者选择应考虑毒性风险,并优先在临床试验框架内进行。
- 需要开发能更好反映PI3K/AKT/mTOR通路功能活性的生物标志物以优化患者选择。
局限性
- 纳入研究数量有限(19项),总样本量较小(233例)。
- 亚组分析中生物标志物选择与未选择人群的CBR差异未达统计学显著性(P=0.217)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the clinical benefit of monotherapy with PI3K/AKT/mTOR inhibitors in patients diagnosed with advanced or recurrent ovarian cancer and to investigate the predictive value of current PI3K/AKT/mTOR biomarkers on therapy response. METHODS: A systematic search was conducted in PubMed, Embase and the Cochrane Library for articles reporting on treatment with PI3K/AKT/mTOR inhibitors in ovarian cancer. The primary endpoint was defined as the clinical benefit rate (CBR), including the proportion of patients with complete (CR) and partial response (PR) and stable disease (SD). Secondary endpoints included the overall response rate (ORR, including CR and PR) and drug-related grade 3 and 4 adverse events. RESULTS: We included 233 patients from 19 studies and observed a pooled CBR of 32% (95% CI 20-44%) and ORR of 3% (95% CI 0-6%) in advanced or recurrent ovarian cancer patients treated with PI3K/AKT/mTOR inhibitors. Subgroup analysis tended to favor the studies who selected patients based on current PI3K/AKT/mTOR biomarker criteria (e.g. genomic alterations or loss of PTEN protein expression), but the difference in CBR was not statistically significant from studies with unselected populations (respectively, CBR of 42% (95% CI 23-62%) and 27% (95% CI 14-42%), P = 0.217). To better reflect true patient benefit, we excluded SD <6 months as a beneficial outcome which resulted in a pooled CBR of 7% (95% CI 2-13%). The overall proportion of patients with drug-related grade 3 and 4 adverse events was 36%. CONCLUSIONS: The efficacy of monotherapy with PI3K/AKT/mTOR inhibitors in advanced recurrent ovarian cancer patients is limited to a small subgroup and selection of patients with the use of current biomarkers did not improved the CBR significantly. Given the toxicity profile, we suggest that current treatment with PI3K/AKT/mTOR inhibitors should not be initiated unless in clinical trials. Furthermore, improved biomarkers to measure functional PI3K/AKT/mTOR pathway activity are needed to optimize patient selection.
引用
- van der Ploeg P, Uittenboogaard A, Thijs AMJ, et al. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis. Gynecol Oncol. 2021. PMID: 34253390. doi:10.1016/j.ygyno.2021.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。